Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - rivaroxaban, quantity: 2.5 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; croscarmellose sodium; hypromellose; magnesium stearate; sodium lauryl sulfate; titanium dioxide; iron oxide yellow; macrogol 6000; iron oxide red; quinoline yellow aluminium lake - rivaroxaban is indicated for:,? prevention of venous thromboembolism (vte) in adult patients who have undergone major orthopaedic surgery of the lower limbs (elective total hip replacement, treatment for up to 5 weeks; elective total knee replacement, treatment for up to 2 weeks),? prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke,? treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe) and for the prevention of recurrent dvt and pe,rivaroxaban, in combination with aspirin, is indicated for:,? the prevention of major cardiovascular events (composite of stroke, myocardial infarction and cardiovascular death) in patients with coronary artery disease (cad) and/or peripheral artery disease (pad)

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - rivaroxaban, quantity: 20 mg - tablet, film coated - excipient ingredients: poloxamer; hypromellose; magnesium stearate; lactose monohydrate; croscarmellose sodium; microcrystalline cellulose; titanium dioxide; macrogol 8000; iron oxide red; iron oxide black - rivaroxaban is indicated for:,? prevention of venous thromboembolism (vte) in adult patients who have undergone major orthopaedic surgery of the lower limbs (elective total hip replacement, treatment for up to 5 weeks; elective total knee replacement, treatment for up to 2 weeks),? prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke,? treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe) and for the prevention of recurrent dvt and pe,rivaroxaban, in combination with aspirin, is indicated for:,? the prevention of major cardiovascular events (composite of stroke, myocardial infarction and cardiovascular death) in patients with coronary artery disease (cad) and/or peripheral artery disease (pad)

Indie - angličtina - Central Drugs Standard Control Organization

alembic - nepafenac - 1mg(0.005%v/v benzalkonium chloride) - 5ml bottle

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - duloxetine hydrochloride, quantity: 33.65 mg - capsule, enteric - excipient ingredients: indigo carmine; triethyl citrate; gelatin; hypromellose phthalate; purified talc; sucrose; hypromellose; titanium dioxide; maize starch; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; iron oxide yellow; shellac; strong ammonia solution - duloxetine capsules are indicated for the treatment of major depressive disorder (mdd).,treatment of diabetic peripheral neuropathic pain (dpnp). treatment of generalised anxiety disorder (gad). duloxetine capsules are indicated for the treatment of major depressive disorder (mdd).,treatment of diabetic peripheral neuropathic pain (dpnp). treatment of generalised anxiety disorder (gad).

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - duloxetine hydrochloride, quantity: 67.3 mg - capsule, enteric - excipient ingredients: gelatin; sucrose; hypromellose; triethyl citrate; purified talc; hypromellose phthalate; titanium dioxide; indigo carmine; iron oxide yellow; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia; potassium hydroxide; maize starch - duloxetine capsules are indicated for the treatment of major depressive disorder (mdd).,treatment of diabetic peripheral neuropathic pain (dpnp). treatment of generalised anxiety disorder (gad).

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - irbesartan, quantity: 300 mg; hydrochlorothiazide, quantity: 25 mg - tablet, film coated - excipient ingredients: magnesium stearate; croscarmellose sodium; lactose monohydrate; povidone; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 4000; iron oxide black - for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - hydrochlorothiazide, quantity: 12.5 mg; irbesartan, quantity: 300 mg - tablet, film coated - excipient ingredients: povidone; lactose monohydrate; magnesium stearate; croscarmellose sodium; iron oxide yellow; iron oxide red; titanium dioxide; hypromellose; macrogol 4000 - for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - irbesartan, quantity: 150 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet, film coated - excipient ingredients: povidone; lactose monohydrate; croscarmellose sodium; magnesium stearate; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 4000 - for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - venlafaxine hydrochloride, quantity: 254.7 mg (equivalent: venlafaxine, qty 225 mg) - capsule, modified release - excipient ingredients: microcrystalline cellulose; povidone; purified talc; colloidal anhydrous silica; magnesium stearate; ethylcellulose; copovidone; carmoisine; titanium dioxide; gelatin; propylene glycol; indigo carmine; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution - venlafaxine extended release capsule is indicated for the treatment of: major depression, including prevention of relapse and recurrence where appropriate; generalised anxiety disorder; social anxiety disorder; panic disorder, including prevention of relapse.

Spojené státy - angličtina - NLM (National Library of Medicine)

alembic pharmaceuticals inc. - temazepam (unii: chb1qd2qss) (temazepam - unii:chb1qd2qss) - temazepam capsules are indicated for the short-term treatment of insomnia (generally 7 to 10 days). for patients with short-term insomnia, instructions in the prescription should indicate that temazepam capsules should be used for short periods of time (7 to 10 days). the clinical trials performed in support of efficacy were 2 weeks in duration with the final formal assessment of sleep latency performed at the end of treatment. controlled substance temazepam capsule contains temazepam, a schedule iv controlled substance. abuse temazepam capsule is a benzodiazepine and a cns depressant with a potential for abuse and addiction. abuse is the intentional, non-therapeutic use of a drug, even once, for its desirable psychological or physiological effects. misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a healthcare provider or for whom it was not prescribed. drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that ma